E-LIB Suche - Ergebnisse für: Zagoya, Carlos

1

Differential Alterations of Expression of the Serotoninergi..:

Martínez-Magaña, José Jaime ; Genis-Mendoza, Alma Delia ; Gallegos-Silva, Ileana...
Nutrients. 16 (2024) 4 - p. 490 , 2024

Link: https://doi.org/10.3390/..

2

Scoring Abdominal Symptoms in People with Cystic Fibrosis:

Tabori, Harold ; Barucha, Anton ; Zagoya, Carlos...
Journal of Clinical Medicine. 13 (2024) 6 - p. 1650 , 2024

Link: https://doi.org/10.3390/..

3

Cross-cultural adaptation and validation of the CFAbd-Score..:

Infantes, Flávia N.S. ; Lomazi, Elizete A. ; Zagoya, Carlos...
Jornal de Pediatria. , 2024

Link: https://doi.org/10.1016/..

4

Reduction in abdominal symptoms (CFAbd-Score), faecal M2-py..:

Mainz, Jochen G. ; Lester, Karen ; Elnazir, Basil...
Journal of Cystic Fibrosis. 23 (2024) 3 - p. 474-480 , 2024

Link: https://doi.org/10.1016/..

5

Chronic rhinosinusitis in people with CF, a rapidly changin..:

Mainz, Jochen G. ; Duckstein, Franziska ; Zagoya, Carlos.
Journal of Cystic Fibrosis. 23 (2024) 2 - p. 183-184 , 2024

Link: https://doi.org/10.1016/..

6

Implementation of a roadmap for the comprehensive diagnosis..:

Núñez-Enríquez, Juan Carlos ; Romo-Rodríguez, Rubí ; Gaspar-Mendoza, Pedro...
Frontiers in Oncology. 14 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

7

Dynamics of abdominal symptoms during the start of a new th..:

Mainz, Jochen G. ; Barucha, Anton ; Huang, Pu...
Frontiers in Pharmacology. 14 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

8

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment red..:

Mainz, Jochen G. ; Zagoya, Carlos ; Polte, Louise...
Frontiers in Pharmacology. 14 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

9

The spatialization of social capital in the collective mana..:

Custodio González, Carlos Alejandro ; Pérez Verdín, Gustavo ; Sánchez Ortiz, Eduardo..
Journal of Environmental Policy & Planning. 26 (2023) 1 - p. 60-74 , 2023

Link: https://doi.org/10.1080/..

10

DataSheet1_Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduc..:

Jochen G. Mainz ; Carlos Zagoya ; Louise Polte...
doi:10.3389/fphar.2022.877118.s001. , 2023

Link: https://doi.org/10.3389/..

11

Dynamics of abdominal symptoms during the start of a new th..:

Jochen G. Mainz ; Anton Barucha ; Pu Huang...
https://www.frontiersin.org/articles/10.3389/fphar.2023.1167407/full. , 2023

Link: https://doi.org/10.3389/..

12

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment red..:

Mainz, Jochen G ; Zagoya, Carlos ; Polte, Louise...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189544/. , 2023

Link: http://www.ncbi.nlm.nih...

13

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment red..:

Jochen G. Mainz ; Carlos Zagoya ; Louise Polte...
https://www.frontiersin.org/articles/10.3389/fphar.2023.1207356/full. , 2023

Link: https://doi.org/10.3389/..

14

Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdomina..:

Mainz, Jochen G. ; Zagoya, Carlos ; Polte, Louise...
Frontiers in Pharmacology. 13 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

15

Divergent dynamics of inflammatory mediators and multiplex ..:

Erdmann, Nina ; Schilling, Theresa ; Hentschel, Julia...
Frontiers in Immunology. 13 (2022) - p. , 2022

Link: https://doi.org/10.3389/..